Arrivent Biopharma Inc (AVBP) Stock Price, Quote & News

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology

Sector: Healthcare

Phone: 628 277 4836

Website: arrivent.com

Address:

18 Campus Boulevard, Suite 100, Newtown Square, United States

laaarsas Jul. 21 at 2:16 PM

$AVBP More slurp???

0 · Reply

laaarsas Jul. 21 at 11:42 AM

$AVBP I need data! Can’t stand to wait any longer!!

0 · Reply

laaarsas Jul. 21 at 10:45 AM

$AVBP Big slurp today too?

0 · Reply

laaarsas Jul. 20 at 7:28 PM

$AVBP Omg what is happening??

2 · Reply

laaarsas Jul. 20 at 5:51 PM

$AVBP Why big slurp?

1 · Reply

justiceforb_85 Jul. 20 at 5:26 PM

$AVBP concerning price action. Data release soon. Hopefully can prove the doubters wrong.

1 · Reply

justiceforb_85 Jul. 18 at 6:36 PM

$AVBP sunvozertinib had no significant benefit compared with chemo in the NEJM article. Cautiously optimistic that the CNS activity and better tolerability of firmonertinib will make this a good readout. Good luck to all!

1 · Reply

laaarsas Jul. 17 at 11:04 AM

$AVBP The longer time the topline stretches, it becomes more likely AVBP will show stat sig over chemo. There is no plateu for the chemo group that can push PFS to extreme levels. Patient temporal drift effect could still be very real. I don't think we are there yet but i results have not come by september, I think the probability for PE met is higher. This is sort of a hunch with the timeline. You can run this reasoning through AI. We are approaching pooled PFS-number on the higher end compared to similar trials. However there is a 2:1 randomization which must be kept in mind.

2 · Reply

justiceforb_85 Jul. 5 at 12:13 AM

$AVBP think we have a home run if the previously reported data for CNS activity with firmonertinib pans out given sunvozertinib showed no significant efficacy in those with baseline CNS disease.

1 · Reply

judgeyoung2 Jun. 24 at 6:41 PM

$AVBP @cubie can you post today’s biggest trades

0 · Reply

ArriVent BioPharma Transcript: AGM 2026

2026-05-29T14:49:43.000Z - 7 weeks ago

ArriVent Biopharma assumed with a Buy at Truist

2026-05-13T10:44:40.000Z - 2 months ago

ArriVent Biopharma price target lowered to $43 from $45 at Citi

2026-05-11T21:38:55.000Z - 2 months ago

ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)

May 11, 2026, 4:01 PM EDT - 2 months ago

ArriVent BioPharma Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 2 months ago

ArriVent BioPharma Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

ArriVent BioPharma Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

ArriVent BioPharma Slides: Corporate presentation

2026-05-07T18:45:02.000Z - 2 months ago

ArriVent Biopharma announces FDA clearance of ARR-002 NDA

May 7, 2026, 8:00 AM EDT - 2 months ago

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Apr 28, 2026, 8:00 AM EDT - 3 months ago

ArriVent BioPharma Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

ArriVent BioPharma Proxy statement: Proxy filing

2026-04-24T11:06:33.000Z - 3 months ago

Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’

2026-03-23T12:51:34.000Z - 4 months ago

ArriVent Biopharma price target raised to $45 from $37 at B. Riley

Mar 17, 2026, 5:00 PM EDT - 4 months ago

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

2026-03-11T20:28:14.000Z - 4 months ago

ArriVent Biopharma assumed with a Buy at BTIG

2026-03-06T12:53:00.000Z - 4 months ago

ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer

2026-03-06T11:15:50.000Z - 4 months ago

ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright

2026-03-06T11:00:30.000Z - 4 months ago

ArriVent Biopharma price target raised to $33 from $31 at Citi

Mar 5, 2026, 4:01 PM EST - 4 months ago

ArriVent BioPharma Reports Full Year 2025 Financial Results

Mar 5, 2026, 9:30 AM EST - 4 months ago

ArriVent BioPharma Annual report: Q4 2025

Mar 5, 2026, 9:30 AM EST - 4 months ago

ArriVent BioPharma Earnings release: Q4 2025

2026-02-17T15:25:37.000Z - 5 months ago

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

ABR AESI APO DMAC ET GEHC MANU

2025-12-22T21:20:44.000Z - 7 months ago

ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

2025-12-22T13:06:00.000Z - 7 months ago

ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study

Dec 22, 2025, 8:00 AM EST - 7 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

2025-12-10T11:46:01.000Z - 7 months ago

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

2025-12-10T11:40:54.000Z - 7 months ago

ArriVent Biopharma initiated with a Buy at BTIG

2025-11-25T11:25:25.000Z - 8 months ago

ArriVent Biopharma initiated with a Buy at Truist

2025-11-11T19:40:25.000Z - 8 months ago

ArriVent Biopharma management to meet virtually with Clear Street

2025-11-11T11:35:58.000Z - 9 months ago

ArriVent Biopharma price target lowered to $31 from $33 at Citi

2025-11-10T13:05:18.000Z - 9 months ago

ArriVent Biopharma reports Q3 EPS (83c), consensus (78c)

Nov 10, 2025, 8:00 AM EST - 9 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 9 months ago

ArriVent BioPharma Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

ArriVent BioPharma Quarterly report: Q3 2025

Sep 22, 2025, 4:05 PM EDT - 10 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 9, 2025, 8:00 AM EDT - 11 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q2 2025

Jul 21, 2025, 8:00 AM EDT - 1 year ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 1, 2025, 11:15 PM EDT - 1 year ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 1 year ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Press release: Study Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Slides: Study Update

Jun 23, 2025, 7:00 AM EDT - 1 year ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 20, 2025, 4:05 PM EDT - 1 year ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Quarterly report: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Proxy statement: Proxy Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Annual report: Q4 2024

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q3 2024

Sep 9, 2024, 12:05 PM EDT - 2 years ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aug 15, 2024, 7:01 AM EDT - 2 years ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 14, 2024, 4:01 PM EDT - 2 years ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:00 PM EDT - 2 years ago

ArriVent BioPharma Quarterly report: Q2 2024

Aug 14, 2024, 4:00 PM EDT - 2 years ago

ArriVent BioPharma Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Jun 5, 2024, 7:00 AM EDT - 2 years ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

May 16, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 8, 2024, 8:00 AM EDT - 2 years ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

ArriVent BioPharma Earnings release: Q1 2024

Apr 22, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints Kristine Peterson to its Board of Directors

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

laaarsas Jul. 21 at 2:16 PM

$AVBP More slurp???

0 · Reply

laaarsas Jul. 21 at 11:42 AM

$AVBP I need data! Can’t stand to wait any longer!!

0 · Reply

laaarsas Jul. 21 at 10:45 AM

$AVBP Big slurp today too?

0 · Reply

laaarsas Jul. 20 at 7:28 PM

$AVBP Omg what is happening??

2 · Reply

laaarsas Jul. 20 at 5:51 PM

$AVBP Why big slurp?

1 · Reply

justiceforb_85 Jul. 20 at 5:26 PM

$AVBP concerning price action. Data release soon. Hopefully can prove the doubters wrong.

1 · Reply

justiceforb_85 Jul. 18 at 6:36 PM

1 · Reply

laaarsas Jul. 17 at 11:04 AM

2 · Reply

justiceforb_85 Jul. 5 at 12:13 AM

$AVBP think we have a home run if the previously reported data for CNS activity with firmonertinib pans out given sunvozertinib showed no significant efficacy in those with baseline CNS disease.

1 · Reply

judgeyoung2 Jun. 24 at 6:41 PM

$AVBP @cubie can you post today’s biggest trades

0 · Reply

judgeyoung2 Jun. 22 at 5:42 PM

$AVBP just need to keep monitoring volume. it’ll tell us when news is about to drop.

1 · Reply

justiceforb_85 Jun. 19 at 2:25 AM

$AVBP crossing fingers that the data for firmonertinib exceeds what has been presented with sunvozertinib in 1L exon 20 tx.

1 · Reply

Doozio Jun. 17 at 8:49 PM

$AVBP out of the tightness …….

0 · Reply

TrendEdgeLogan Jun. 17 at 5:33 PM

$AVBP $1.4B mc Founder-led biotech $XBI Hidden Gem is getting a 'Wait to Buy' recommendation from Trend Edge AI Consult today. Stalking this one for a pullback to the rising 10-week SMA - Pct of all funds at record highs & rising for 8 straight quarters - Short Squeezer underway as Short float % has steadily trended lower over the past 8 months from 34% highs to now 24% TrendEdge.app/asset/AVBP

0 · Reply

judgeyoung2 Jun. 5 at 4:12 PM

$AVBP they wouldn’t let me sell my calls for a fair price yesterday. bastards.

0 · Reply

laaarsas Jun. 5 at 12:00 PM

$AVBP Do you expect efficacy greater, on par with, or worse than WUKONG-28? And why?

1 · Reply

Doozio Jun. 5 at 3:07 AM

$AVBP da huckleberries r thru da $$ ONTO 🐒🍌🧠⏰♾️

0 · Reply

justiceforb_85 Jun. 4 at 7:13 PM

$AVBP lovely movement.

0 · Reply

Doozio Jun. 4 at 2:13 PM

$AVBP it was always ONTO 🐒🍌🧠⏰♾️

0 · Reply

judgeyoung2 Jun. 1 at 6:53 PM

$AVBP action on the 35c strike for this month. do i get back in?

2 · Reply

justiceforb_85 May. 29 at 7:18 PM

$AVBP likely the reason for this to be soaring: https://www.nejm.org/doi/full/10.1056/NEJMoa2604461?query=featured_home.

0 · Reply

Quantumup May. 29 at 4:05 PM

Truist assumed coverage on $AVBP at a Buy rating and a $45 PT (was $43) and said that it views AVBP's firmonertinib as well-positioned across the EGFR Ex20ins and PACC mutation NSCLC landscape. $ORIC JNJ BDTX $CGEM Truist added that its view is supported by an encouraging efficacy and tolerability profile that underpins their $1.1B peak revenue estimate.

0 · Reply

Market Cap	1.55B
Revenue (ttm)	0.00
Net Income (ttm)	-166.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	925,000
Avg Vol	575,922
Day's Range	N/A - N/A
Shares Out	46.58M
Stochastic %K	3%
Beta	1.29
Analysts	Strong Sell
Price Target	$43.92